Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Market movers: Lockheed Martin, General Dynamics, Gap, Constellation Brands...

Gap Inc (NYSE:GPS) shares added nearly 7% on Thursday following an upgrade from UBS, which raised the retailer’s rating from to ‘Buy’ from ‘Neutral’ and increased its price target to $41 from $26.

The move reflects UBS’s confidence in Gap’s ongoing turnaround under CEO Richard Dickson. The analysts cited Gap’s “reinvigoration playbook,” noting that the company is moving from inventory cleanup toward accelerated growth.

Read more

Constellation Brands Inc (NYSE:STZ) shares added more than 4% after the global alcohol producer and marketer’s fiscal third quarter earnings topped analyst expectations despite declines in sales and operating income.

The company posted net sales of $2.22 billion, down 10% from the prior year, while comparable net sales fell 2%. This was above the $2.18 billion Wall Street consensus.

Read more

Alphabet Inc (NASDAQ:GOOG) has surpassed Apple Inc (NASDAQ:AAPL, XETRA:APC) to become the world’s second-most valuable company, trailing only Nvidia Corp (NASDAQ:NVDA, XETRA:NVD).

The move marks the first time Alphabet has topped Apple in market capitalization since 2019.

Read more

President Donald Trump’s plans to request an increase in the US military budget are giving a fresh boost to defense stocks.

Trump has proposed raising the US defense budget to around $1.5 trillion by 2027, up from the current level of approximately $901 billion.

Read more

Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy drug AGAMREE, strengthening its balance sheet and extending its global reach.

Under the agreement, announced on Thursday, Santhera has licensed rights to the treatment in Japan, South Korea, Australia and New Zealand to Nxera Pharma.

Read more

Shell PLC (LSE:SHEL, NYSE:SHEL) issued an update to its fourth quarter outlook on Thursday, flagging to investors softer trading.

In London, the share was down 2.26% changing hands at 2,595p in Thursday morning's trade.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK